Capricor Therapeutics Target of Unusually Large Options Trading (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of some unusual options trading activity on Thursday. Stock investors acquired 11,316 call options on the stock. This represents an increase of 214% compared to the average volume of 3,599 call options.

Capricor Therapeutics Price Performance

CAPR stock opened at $14.36 on Friday. The business has a fifty day moving average price of $14.06 and a 200 day moving average price of $14.50. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The stock has a market capitalization of $652.95 million, a price-to-earnings ratio of -13.55 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. On average, equities analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of CAPR. The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics during the 3rd quarter worth $161,000. FMR LLC acquired a new position in shares of Capricor Therapeutics during the third quarter valued at $370,000. BNP Paribas Financial Markets boosted its holdings in Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 15,872 shares during the last quarter. Fred Alger Management LLC bought a new position in Capricor Therapeutics in the third quarter valued at about $399,000. Finally, PFM Health Sciences LP acquired a new stake in Capricor Therapeutics in the third quarter worth about $2,324,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.